newsfilter
← Latest News
Business Wire·

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. - - Elegrobart, potentially the first subcutaneous